Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Поражения печени, ассоциированные с приемом нестероидных противовоспалительных препаратов, в фокусе клинициста
Поражения печени, ассоциированные с приемом нестероидных противовоспалительных препаратов, в фокусе клинициста
Ахмедов В.А. Поражения печени, ассоциированные с приемом нестероидных противовоспалительных препаратов, в фокусе клинициста. Гастроэнтерология. Хирургия. Интенсивная терапия. Consilium Medicum. 2019; 3: 11–12. DOI: 10.26442/26583739.2019.3.190484
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Поражение органов желудочно-кишечного тракта является частым патологическим процессом, возникающим у пациентов на фоне лечения нестероидными противовоспалительными препаратами (НПВП), что снижает качество жизни больных, обусловливает значительные финансовые потери, возникающие в связи с дорогостоящим лечением. В представленной работе рассмотрены современные взгляды на механизмы поражения печени на фоне приема НПВП и перспективные маркеры диагностики лекарственного поражения печени.
Ключевые слова: нестероидные противовоспалительные препараты, риск, лекарственный гепатит.
Key words: non-steroidal anti-inflammatory drugs, the risk of drug-induced hepatitis.
Ключевые слова: нестероидные противовоспалительные препараты, риск, лекарственный гепатит.
________________________________________________
Key words: non-steroidal anti-inflammatory drugs, the risk of drug-induced hepatitis.
Полный текст
Список литературы
1. Anelli MG, Scioscia C, Grattagliano I et al. Old and new antirheumatic drugs and the risk of hepatotoxicity. Ther Drug Monit 2012; 34 (6): 622–8.
2. Aithal G. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007; 11: 563–75.
3. Bello AE, Kent JD, Grahn AY et al. One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. Curr Med Res Opin 2015; 31 (3): 397–405.
4. Rahme E, Joseph L, Kong SX et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinfl ammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000; 43: 917–24.
5. DeAbajo FJ, Montero D, Madurga M et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71–80.
6. Schmeltzer PA, Kosinski AS, Kleiner DE. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int 2016; 36 (4): 603–9.
7. Aithal GP, Ramsay L, Daly AK et al. Hepatic adducts, circulating an-tibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39: 1430–40.
8. Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory drug-induced hepatoxicity. Clin Liver Dis 2013; 17: 643–56.
9. Teschke R, Frenzel C, Wolff A et al. Drug induced liver injury: Accuracy of diagnosis in published reports. Ann Hepatol 2014; 13: 248–55.
10. Faghihzadeh F, Hekmatdoost A, Adibi P. Resveratrol and liver: A systematic review. J Res Med Sci 2015; 20 (8): 797–810.
11. Reitblat T, Zamir D, Estis L et al. The different patterns of blood pressure elevation by rofecoxib and nabumetone. J Hum Hypertens 2002; 16 (6): 431–4.
12. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16 (45): 5651–61.
13. Laine L, Goldkind L, Curtis SP et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. AJG 2009; 104: 356–62.
14. Fredriksson L, Wink S, Herpers B et al. Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFa-mediated hepatotoxicity. Toxicol Sci 2014; 140 (1): 144–59.
15. Jessurun N, van Puijenbroek E. Relationship between structural alerts in NSAIDs and idiosyncratic hepatotoxicity: an analysis of spontaneous report data from the WHO database. Drug Saf 2015; 38 (5): 511–5.
16. Наумова О.В., Ахмедов В.А. Участие матриксных металлопротеиназ в механизмах формирования НПВП-гепатопатии у больных остеоартрозом. Вестн. Уральской медицинской академической науки. 2012; 2 (39): 89–90.
[Naumova O.V., Akhmedov V.A. Uchastie matriksnykh metalloproteinaz v mekhanizmakh formirovaniia NPVP-gepatopatii u bol'nykh osteoartrozom. Vestn. Ural'skoi meditsinskoi akademicheskoi nauki. 2012; 2 (39): 89–90 (in Russian).]
17. Ахмедов В.А., Наумова О.В. Прогностические факторы формирования и оптимизация ведения больных сочетанным НПВП-ассоциированным поражением желудка и печени у больных остеоартрозом: методические рекомендации. Омск: ОмГМУ, 2018.
[Akhmedov V.A., Naumova O.V. Prognosticheskie faktory formirovaniia i optimizatsiia vedeniia bol'nykh sochetannym NPVP-assotsiirovannym porazheniem zheludka i pecheni u bol'nykh osteoartrozom: metodicheskie rekomendatsii. Omsk: OmGMU, 2018 (in Russian).]
18. Kullak-Ublick GA, Andrade RJ, Merz M et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017; 66: 1154–64.
19. Clarke JI, Dear JW, Antoine DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety – false dawn or new horizon? Expert Opin Drug Saf 2016; 15: 625–34.
2. Aithal G. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007; 11: 563–75.
3. Bello AE, Kent JD, Grahn AY et al. One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. Curr Med Res Opin 2015; 31 (3): 397–405.
4. Rahme E, Joseph L, Kong SX et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinfl ammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000; 43: 917–24.
5. DeAbajo FJ, Montero D, Madurga M et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71–80.
6. Schmeltzer PA, Kosinski AS, Kleiner DE. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int 2016; 36 (4): 603–9.
7. Aithal GP, Ramsay L, Daly AK et al. Hepatic adducts, circulating an-tibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39: 1430–40.
8. Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory drug-induced hepatoxicity. Clin Liver Dis 2013; 17: 643–56.
9. Teschke R, Frenzel C, Wolff A et al. Drug induced liver injury: Accuracy of diagnosis in published reports. Ann Hepatol 2014; 13: 248–55.
10. Faghihzadeh F, Hekmatdoost A, Adibi P. Resveratrol and liver: A systematic review. J Res Med Sci 2015; 20 (8): 797–810.
11. Reitblat T, Zamir D, Estis L et al. The different patterns of blood pressure elevation by rofecoxib and nabumetone. J Hum Hypertens 2002; 16 (6): 431–4.
12. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16 (45): 5651–61.
13. Laine L, Goldkind L, Curtis SP et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. AJG 2009; 104: 356–62.
14. Fredriksson L, Wink S, Herpers B et al. Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFa-mediated hepatotoxicity. Toxicol Sci 2014; 140 (1): 144–59.
15. Jessurun N, van Puijenbroek E. Relationship between structural alerts in NSAIDs and idiosyncratic hepatotoxicity: an analysis of spontaneous report data from the WHO database. Drug Saf 2015; 38 (5): 511–5.
16. Naumova O.V., Akhmedov V.A. Uchastie matriksnykh metalloproteinaz v mekhanizmakh formirovaniia NPVP-gepatopatii u bol'nykh osteoartrozom. Vestn. Ural'skoi meditsinskoi akademicheskoi nauki. 2012; 2 (39): 89–90 (in Russian).
17. Akhmedov V.A., Naumova O.V. Prognosticheskie faktory formirovaniia i optimizatsiia vedeniia bol'nykh sochetannym NPVP-assotsiirovannym porazheniem zheludka i pecheni u bol'nykh osteoartrozom: metodicheskie rekomendatsii. Omsk: OmGMU, 2018 (in Russian).
18. Kullak-Ublick GA, Andrade RJ, Merz M et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017; 66: 1154–64.
19. Clarke JI, Dear JW, Antoine DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety – false dawn or new horizon? Expert Opin Drug Saf 2016; 15: 625–34.
2. Aithal G. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007; 11: 563–75.
3. Bello AE, Kent JD, Grahn AY et al. One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. Curr Med Res Opin 2015; 31 (3): 397–405.
4. Rahme E, Joseph L, Kong SX et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinfl ammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000; 43: 917–24.
5. DeAbajo FJ, Montero D, Madurga M et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71–80.
6. Schmeltzer PA, Kosinski AS, Kleiner DE. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int 2016; 36 (4): 603–9.
7. Aithal GP, Ramsay L, Daly AK et al. Hepatic adducts, circulating an-tibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39: 1430–40.
8. Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory drug-induced hepatoxicity. Clin Liver Dis 2013; 17: 643–56.
9. Teschke R, Frenzel C, Wolff A et al. Drug induced liver injury: Accuracy of diagnosis in published reports. Ann Hepatol 2014; 13: 248–55.
10. Faghihzadeh F, Hekmatdoost A, Adibi P. Resveratrol and liver: A systematic review. J Res Med Sci 2015; 20 (8): 797–810.
11. Reitblat T, Zamir D, Estis L et al. The different patterns of blood pressure elevation by rofecoxib and nabumetone. J Hum Hypertens 2002; 16 (6): 431–4.
12. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16 (45): 5651–61.
13. Laine L, Goldkind L, Curtis SP et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. AJG 2009; 104: 356–62.
14. Fredriksson L, Wink S, Herpers B et al. Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFa-mediated hepatotoxicity. Toxicol Sci 2014; 140 (1): 144–59.
15. Jessurun N, van Puijenbroek E. Relationship between structural alerts in NSAIDs and idiosyncratic hepatotoxicity: an analysis of spontaneous report data from the WHO database. Drug Saf 2015; 38 (5): 511–5.
16. Наумова О.В., Ахмедов В.А. Участие матриксных металлопротеиназ в механизмах формирования НПВП-гепатопатии у больных остеоартрозом. Вестн. Уральской медицинской академической науки. 2012; 2 (39): 89–90.
[Naumova O.V., Akhmedov V.A. Uchastie matriksnykh metalloproteinaz v mekhanizmakh formirovaniia NPVP-gepatopatii u bol'nykh osteoartrozom. Vestn. Ural'skoi meditsinskoi akademicheskoi nauki. 2012; 2 (39): 89–90 (in Russian).]
17. Ахмедов В.А., Наумова О.В. Прогностические факторы формирования и оптимизация ведения больных сочетанным НПВП-ассоциированным поражением желудка и печени у больных остеоартрозом: методические рекомендации. Омск: ОмГМУ, 2018.
[Akhmedov V.A., Naumova O.V. Prognosticheskie faktory formirovaniia i optimizatsiia vedeniia bol'nykh sochetannym NPVP-assotsiirovannym porazheniem zheludka i pecheni u bol'nykh osteoartrozom: metodicheskie rekomendatsii. Omsk: OmGMU, 2018 (in Russian).]
18. Kullak-Ublick GA, Andrade RJ, Merz M et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017; 66: 1154–64.
19. Clarke JI, Dear JW, Antoine DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety – false dawn or new horizon? Expert Opin Drug Saf 2016; 15: 625–34.
________________________________________________
2. Aithal G. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis 2007; 11: 563–75.
3. Bello AE, Kent JD, Grahn AY et al. One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. Curr Med Res Opin 2015; 31 (3): 397–405.
4. Rahme E, Joseph L, Kong SX et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinfl ammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000; 43: 917–24.
5. DeAbajo FJ, Montero D, Madurga M et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71–80.
6. Schmeltzer PA, Kosinski AS, Kleiner DE. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int 2016; 36 (4): 603–9.
7. Aithal GP, Ramsay L, Daly AK et al. Hepatic adducts, circulating an-tibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 2004; 39: 1430–40.
8. Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory drug-induced hepatoxicity. Clin Liver Dis 2013; 17: 643–56.
9. Teschke R, Frenzel C, Wolff A et al. Drug induced liver injury: Accuracy of diagnosis in published reports. Ann Hepatol 2014; 13: 248–55.
10. Faghihzadeh F, Hekmatdoost A, Adibi P. Resveratrol and liver: A systematic review. J Res Med Sci 2015; 20 (8): 797–810.
11. Reitblat T, Zamir D, Estis L et al. The different patterns of blood pressure elevation by rofecoxib and nabumetone. J Hum Hypertens 2002; 16 (6): 431–4.
12. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16 (45): 5651–61.
13. Laine L, Goldkind L, Curtis SP et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. AJG 2009; 104: 356–62.
14. Fredriksson L, Wink S, Herpers B et al. Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFa-mediated hepatotoxicity. Toxicol Sci 2014; 140 (1): 144–59.
15. Jessurun N, van Puijenbroek E. Relationship between structural alerts in NSAIDs and idiosyncratic hepatotoxicity: an analysis of spontaneous report data from the WHO database. Drug Saf 2015; 38 (5): 511–5.
16. Naumova O.V., Akhmedov V.A. Uchastie matriksnykh metalloproteinaz v mekhanizmakh formirovaniia NPVP-gepatopatii u bol'nykh osteoartrozom. Vestn. Ural'skoi meditsinskoi akademicheskoi nauki. 2012; 2 (39): 89–90 (in Russian).
17. Akhmedov V.A., Naumova O.V. Prognosticheskie faktory formirovaniia i optimizatsiia vedeniia bol'nykh sochetannym NPVP-assotsiirovannym porazheniem zheludka i pecheni u bol'nykh osteoartrozom: metodicheskie rekomendatsii. Omsk: OmGMU, 2018 (in Russian).
18. Kullak-Ublick GA, Andrade RJ, Merz M et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 2017; 66: 1154–64.
19. Clarke JI, Dear JW, Antoine DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety – false dawn or new horizon? Expert Opin Drug Saf 2016; 15: 625–34.
Авторы
В.А. Ахмедов*
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*v_akhmedov@mail.ru
Omsk State Medical University, Omsk, Russia
*v_akhmedov@mail.ru
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*v_akhmedov@mail.ru
________________________________________________
Omsk State Medical University, Omsk, Russia
*v_akhmedov@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.